A guide to tadalafil (Cialis) covering dosing, mechanism, head-to-head comparisons with sildenafil, vardenafil, avanafil, and alprostadil, plus side effects and who qualifies.
A guide to DHEA, testosterone cypionate, enanthate, propionate, and pellets for men's TRT. Covers mechanisms, dosing, pharmacokinetics, and how to choose the right formulation.
Primary hypogonadism originates in the testes; secondary hypogonadism originates in the pituitary or hypothalamus. The distinction changes every treatment decision, including whether TRT alone is appropriate or whether fertility must be preserved with gonadotropin therapy.
A complete clinical guide to testosterone nasal gel (Natesto), covering FDA-approved dosing, pharmacokinetics, side effects, and how it stacks up against cypionate, enanthate, propionate, and pellets.
A guide to oral testosterone undecanoate (Jatenzo): FDA approval, dosing, blood pressure risks, and head-to-head comparison with testosterone cypionate, enanthate, propionate, and pellets.
A complete clinical guide to testosterone pellets for men on TRT, including how subcutaneous implants compare to testosterone cypionate, enanthate, propionate, and AndroGel on efficacy, dosing, and convenience.
A guide to total testosterone reference ranges, free testosterone calculation, estradiol sensitive assay, CBC, and lipid panel monitoring during TRT.
Can testosterone replacement therapy treat depression in men with low T? Review the clinical evidence, mechanisms, dosing, and how TRT compares with antidepressants.
Low testosterone is a documented cause of chronic fatigue in men with confirmed hypogonadism. Learn what the evidence actually supports, what remains uncertain, and how to get properly diagnosed before considering TRT.
Learn how TRT addresses muscle loss from low testosterone, what the clinical trials show on lean mass gains, who qualifies, and how to start treatment safely.
Evidence-based guide to testosterone replacement therapy (TRT) for osteoporosis in men with hypogonadism. Covers bone density data, dosing, monitoring, and how TRT compares with bisphosphonates.
A board-reviewed guide to testosterone replacement therapy for transgender men, covering dosing, timelines, monitoring, fertility, and age-specific considerations from under-30 to over-65.
A guide to testosterone replacement therapy for men over 50, covering eligibility, dosing protocols, cardiovascular safety, bone health, and how TRT differs across age groups including men over 65.
A comparison of testosterone replacement therapy (TRT) vs clomiphene (Clomid) and enclomiphene for low testosterone, covering efficacy, fertility, side effects, and how to choose between cypionate, enanthate, and gel formulations.
A guide to combining TRT with GLP-1 receptor agonists like semaglutide or tirzepatide. Covers dosing, timing, who qualifies, monitoring, and what the clinical evidence actually supports and does not yet support for men at different ages.
A practical, clinician-backed guide to reading health research studies without getting lost in statistics, p-values, or industry spin. Learn exactly how to evaluate a trial, guideline, or meta-analysis before making any health decision.
A guide to metformin monitoring in adolescents aged 12 to 17, covering lab schedules, dose titration, growth considerations, mental-health screening, and safety signals.
Evidence-based metformin dosing for adults aged 30 to 49, covering starting doses, titration schedules, maximum doses, renal thresholds, and real-world considerations for working-age patients with type 2 diabetes or prediabetes.
A clinical and coverage guide to Aetna (CVS Health) metformin coverage, prior authorization criteria, formulary tiers, step therapy requirements, and appeal pathways for type 2 diabetes and prediabetes.
A complete guide to Blue Cross Blue Shield (Federated) coverage for metformin, including formulary tiers, prior authorization, step therapy, appeals, and out-of-pocket cost options.
Metformin interacts with alcohol, high-fat meals, berberine, B12, magnesium, and calcium. See dosing context, trial data, and monitoring thresholds.
A guide to using metformin for metabolic syndrome: what the trial data shows, how to dose it, who qualifies, and what side effects to watch for.
A state-by-state guide to Medicaid coverage of metformin for type 2 diabetes and prediabetes, including formulary tiers, prior authorization criteria, step therapy rules, and how to appeal a denial.
A complete guide to Medicare Advantage metformin coverage, formulary tiers, prior authorization, step therapy, and how to appeal a denial, with clinical context.
Complete guide to monitoring children under 12 on metformin: dosing, labs, growth checks, GI side effects, and when to stop. Reviewed by HealthRX.com physicians.
A clinician-level review of metformin pharmacogenomics, covering SLC22A1, SLC47A1, ATM, and other variants that explain why response to metformin differs so dramatically between patients.
Metformin dosing by eGFR: full dose above 60, reduced dose 30-59 with monitoring, contraindicated below 30 mL/min/1.73 m2 per FDA label.
Everything a young adult (18-29) needs to know about metformin monitoring: which labs to check, how often, warning signs, fertility considerations, and how to stay safe long-term.
A clinician-level review of metformin's effects on the kidney: emerging evidence for renal protection, updated eGFR dosing thresholds, lactic acidosis risk, and the 2023 ADA/KDIGO guidance on safe use in CKD.
A clinical guide to monitoring MK-677 (ibutamoren) use in adults aged 30 to 49: which labs to order, how often, what thresholds matter, and what side effects to watch for.
A breakdown of MK-677 (ibutamoren) safety data for adults ages 30 to 49, covering adverse effects, IGF-1 risks, insulin resistance, and how to weigh the limited evidence before considering use.
A synthesis of MK-677 (ibutamoren) real-world evidence, mechanism of action, clinical trial data, and safety signals. Includes inline PubMed citations throughout.
A week-by-week guide to MK-677 (ibutamoren) effects during the first month: GH/IGF-1 timelines, sleep changes, side effects, and clinical context, with clear notes on what is established versus anecdotal.
Why MK-677 stops working and how to fix it: a clinician-level guide to ibutamoren plateaus, desensitization, dosing errors, and lab-confirmed non-response with primary-literature support.
A guide to discontinuing MOTS-c (mitochondrial open reading frame of the 12S rRNA-c) safely, covering mechanism, tapering rationale, metabolic rebound risk, and what the evidence actually shows.
A physician-level review of MOTS-c mitochondrial peptide use in transplant recipients, people living with HIV, older adults, and other special populations. Covers mechanism, dosing, safety signals, and current evidence.
A clinical review of MOTS-c mitochondrial peptide and its impact on cognitive function, covering mechanisms, animal data, emerging human research, and what patients considering this peptide should know.
A clinician-level review of what happens when you stop MOTS-c peptide therapy, whether rebound metabolic effects are real, what the mitochondrial biology predicts, and how to discontinue safely based on current research.
A guide to tirzepatide (Mounjaro) dosing in adolescents aged 12 to 17, covering FDA approval status, titration schedules, safety monitoring, and the latest trial evidence.
A guide to tirzepatide safety in adolescents ages 12 to 17, covering trial evidence, dosing, growth monitoring, mental-health considerations, and FDA approval status.
A guide to using tirzepatide (Mounjaro) for menopause-related weight gain, covering clinical trial data, dosing protocols, HRT combinations, and realistic outcomes.
A guide to using tirzepatide (Mounjaro) for obesity with BMI ≥30, covering SURMOUNT trial data, weekly dosing schedules, side-effect management, and insurance realities.
A guide to using tirzepatide (Mounjaro) for PCOS: trial evidence, dosing schedules, hormonal effects, insulin resistance benefits, and how to talk to your provider about off-label use.
Tirzepatide (Mounjaro) is used off-label for prediabetes in high-risk patients. Review the clinical trial data, dosing schedules, side-effect profile, and insurance realities before starting treatment.
Complete clinical guide to the Mounjaro (tirzepatide) missed-dose protocol, including timing rules, what to skip, pharmacokinetic reasoning, and how tirzepatide's dual GIP/GLP-1 mechanism shapes dosing decisions.
A complete guide to the Mounjaro (tirzepatide) monitoring schedule, covering baseline labs, follow-up bloodwork, vital signs, and exam intervals backed by FDA labeling, ADA guidelines, and primary clinical trials.
A comprehensive guide to tirzepatide (Mounjaro) dosing in children under 12, covering FDA approval status, off-label use, safety data, and clinical decision-making frameworks for pediatric type 2 diabetes.
A guide to switching between tirzepatide (Mounjaro) and other GLP-1 or dual GIP/GLP-1 medications, including semaglutide, dulaglutide, and liraglutide. Covers mechanism, dose conversion, washout timing, and clinical evidence.
A guide to how Mounjaro (tirzepatide) reduces appetite and alters food cravings, covering the dual GIP/GLP-1 mechanism, trial data from SURMOUNT and SURPASS, and what patients typically experience week by week.
A clinician-level review of tirzepatide (Mounjaro) use in patients with autoimmune conditions, covering immunomodulatory mechanisms, disease-specific risks, monitoring protocols, and the latest trial evidence.
Does Mounjaro (tirzepatide) improve or impair cognitive function? A clinician-level review of the trial data, proposed mechanisms, and what patients with type 2 diabetes or obesity can realistically expect.
A GRADE-level review of tirzepatide (Mounjaro) clinical trial evidence, covering glycemic control, weight loss, cardiovascular outcomes, and safety across the SURPASS program and beyond.
A guide to tirzepatide-related hair loss, skin changes, and nail effects. Covers the science behind GLP-1/GIP-driven telogen effluvium, clinical evidence, and what patients can do.
A deep dive into how tirzepatide (Mounjaro) alters resting metabolic rate, fat oxidation, thermogenesis, and energy expenditure, with primary-literature citations and real dosing data.
Step-by-step clinical protocol for restarting Mounjaro (tirzepatide) after acute illness, including dose step-down rules, hydration checks, GI monitoring, and evidence from SURPASS trials.
A clinical deep-dive into tirzepatide's effects on kidney function, including eGFR trends, albuminuria data from SURPASS trials, and the SURMOUNT-4 renal sub-analysis. Board-prepared by the HealthRX.com Editorial Team.
Aetna generally does not cover NMN or NR as dietary supplements. Learn exactly when coverage applies, how prior authorization works, how to appeal a denial, and what cash-pay options exist.
A guide to discontinuing NMN and NR supplementation safely, covering NAD+ biology, rebound effects, taper protocols, and what the clinical evidence actually shows.
A guide to NMN and NR overdose risk, toxicology, mechanism of action, and management steps when someone takes too much nicotinamide mononucleotide or nicotinamide riboside.
An evidence-based guide to NMN and NR supplement safety during pregnancy and breastfeeding, covering mechanism, human trial data, animal studies, and clinical recommendations.